bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplemental Figure S2 from Loss of ARID1A Activates ANXA1, which Serves as a Predictive Biomarker for Trastuzumab Resistance
Authors: Berns Katrien , Sonnenblick Amir , Gennissen Annemiek , Brohée Sylvain , Hijmans E. Marielle , Evers Bastiaan , Fumagalli Debora , Desmedt Christine , Loibl Sibylle , Denkert Carsten , Neven Patrick , Guo Wei , Zhang Fan , Knijnenburg Theo A. , Bosse Tjalling , van der Heijden Michiel S. , Hindriksen Sanne , Nijkamp Wouter , Wessels Lodewyk F.A. , Joensuu Heikki , Mills Gordon B. , Beijersbergen Roderick L. , Sotiriou Christos , Bernards René
Published: April 2023

Supplemental Figure S2: Suppression of ARID1A leads to induction of ANXA1 RNA expression and loss of BRG1 complex binding to ANXA1 region
Figure S2 from Gene Copy Number Estimation from Targeted Next-Generation Sequencing of Prostate Cancer Biopsies: Analytic Validation and Clinical Qualification
Authors: Seed George , Yuan Wei , Mateo Joaquin , Carreira Suzanne , Bertan Claudia , Lambros Maryou , Boysen Gunther , Ferraldeschi Roberta , Miranda Susana , Figueiredo Ines , Riisnaes Ruth , Crespo Mateus , Rodrigues Daniel Nava , Talevich Eric , Robinson Dan R. , Kunju Lakshmi P. , Wu Yi-Mi , Lonigro Robert , Sandhu Shahneen , Chinnaiyan Arul M. , de Bono Johann S.
Published: April 2023

RB1 FISH from sample p.16.0 showing RB1 (red) and reference (green) showing a mixture of: hemizygously deleted cells (white arrows) and homozygously deleted cells (orange arrows).
Figure S2 from HMGA2–FOXL2 Axis Regulates Metastases and Epithelial-to-Mesenchymal Transition of Chemoresistant Gastric Cancer
Authors: Dong Jiaqiang , Wang Rui , Ren Gui , Li Xiaowei , Wang Jingbo , Sun Yi , Liang Jie , Nie Yongzhan , Wu Kaichun , Feng Bin , Shang Yulong , Fan Daiming
Published: April 2023

RT-PCR analysis of HMGA2-FOXL2 pathway associated molecules. A. The mRNA expression levels of E-cadherin, Vimentin, Snail1 and ZEB2 were analysed when FOXL2 was suppressed. **P<0.01. B. The alterations to E-cadherin, Vimentin and Snail1 was analysed after HMGA2 was knocked down. **P<0.01. C. The alterations to E-cadherin, Vimentin, Snail1 and ZEB2 caused by ectopic FOXL2. **P<0.01. D. The effects of ectopic HMGA2 on E-cadherin, Vimentin and Snail1. **P<0.01. E. CDC2, CCNE1 and TK1 were increased by ectopic E2F1 and HMGA2. **P<0.01. F. Knockdown of E2F1 suppressed CDC2, CCNE1 and TK1. **P<0.01. G. CDC2, CCNE1 and TK1 were increased by inhibiting Rb. **P<0.01.
Supplementary Table S5 from A Multicenter Phase I Study Evaluating Dual PI3K and BRAF Inhibition with PX-866 and Vemurafenib in Patients with Advanced BRAF V600–Mutant Solid Tumors
Authors: Yam Clinton , Xu Xiaowei , Davies Michael A. , Gimotty Phyllis A. , Morrissette Jennifer J.D. , Tetzlaff Michael T. , Wani Khalida M. , Liu Shujing , Deng Wanleng , Buckley Meghan , Zhao Jianhua , Amaravadi Ravi K. , Haas Naomi B. , Kudchadkar Ragini R. , Pavlick Anna C. , Sosman Jeffrey A. , Tawbi Hussein , Walker Luke , Schuchter Lynn M. , Karakousis Giorgos C. , Gangadhar Tara C.
Published: April 2023

Changes in protein expression in paired samples (n=3) obtained before and after treatment with PX-866. A table comparing protein expression levels between tumor biopsy specimens obtained at baseline and on C1D8.
Supplementary Table Legends from A Multicenter Phase I Study Evaluating Dual PI3K and BRAF Inhibition with PX-866 and Vemurafenib in Patients with Advanced BRAF V600–Mutant Solid Tumors
Authors: Yam Clinton , Xu Xiaowei , Davies Michael A. , Gimotty Phyllis A. , Morrissette Jennifer J.D. , Tetzlaff Michael T. , Wani Khalida M. , Liu Shujing , Deng Wanleng , Buckley Meghan , Zhao Jianhua , Amaravadi Ravi K. , Haas Naomi B. , Kudchadkar Ragini R. , Pavlick Anna C. , Sosman Jeffrey A. , Tawbi Hussein , Walker Luke , Schuchter Lynn M. , Karakousis Giorgos C. , Gangadhar Tara C.
Published: April 2023

Legends for Supplementary Tables S1-S6
Supplementary Table 4 from Multifaceted Role of BTLA in the Control of CD8+ T-cell Fate after Antigen Encounter
Authors: Ritthipichai Krit , Haymaker Cara L. , Martinez Melisa , Aschenbrenner Andrew , Yi Xiaohui , Zhang Minying , Kale Charuta , Vence Luis M. , Roszik Jason , Hailemichael Yared , Overwijk Willem W. , Varadarajan Navin , Nurieva Roza , Radvanyi Laszlo G. , Hwu Patrick , Bernatchez Chantale
Published: April 2023

RPPA data of mouse OT-1 T cells expressing WT BTLA or BTLA variants stimulated with anti-CD3 and HVEM-FC
Figure S3 from The c.1085A>G Genetic Variant of CSF1R Gene Regulates Tumor Immunity by Altering the Proliferation, Polarization, and Function of Macrophages
Authors: Yeh Yu-Min , Hsu Shan-Ju , Lin Peng-Chan , Hsu Keng-Fu , Wu Pei-Ying , Su Wu-Chou , Chang Jang-Yang , Shen Meng-Ru
Published: April 2023

The clinical characteristics and survival difference of endometrial and ovarian cancer patients with CSF1R c.1085 genotype A_A and A_G.
Supplementary Figure 2 from Multifaceted Role of BTLA in the Control of CD8+ T-cell Fate after Antigen Encounter
Authors: Ritthipichai Krit , Haymaker Cara L. , Martinez Melisa , Aschenbrenner Andrew , Yi Xiaohui , Zhang Minying , Kale Charuta , Vence Luis M. , Roszik Jason , Hailemichael Yared , Overwijk Willem W. , Varadarajan Navin , Nurieva Roza , Radvanyi Laszlo G. , Hwu Patrick , Bernatchez Chantale
Published: April 2023

Expression of BTLA in murine CD8+ T cells according to differentiation status.
Movie 3 from Multifaceted Role of BTLA in the Control of CD8+ T-cell Fate after Antigen Encounter
Authors: Ritthipichai Krit , Haymaker Cara L. , Martinez Melisa , Aschenbrenner Andrew , Yi Xiaohui , Zhang Minying , Kale Charuta , Vence Luis M. , Roszik Jason , Hailemichael Yared , Overwijk Willem W. , Varadarajan Navin , Nurieva Roza , Radvanyi Laszlo G. , Hwu Patrick , Bernatchez Chantale
Published: April 2023

Movie 3 from Multifaceted Role of BTLA in the Control of CD8+ T-cell Fate after Antigen Encounter
Tables S1-S3 and Figures S1-S2 from APOBEC3G Expression Correlates with T-Cell Infiltration and Improved Clinical Outcomes in High-grade Serous Ovarian Carcinoma
Authors: Leonard Brandon , Starrett Gabriel J. , Maurer Matthew J. , Oberg Ann L. , Van Bockstal Mieke , Van Dorpe Jo , De Wever Olivier , Helleman Jozien , Sieuwerts Anieta M. , Berns Els M.J.J. , Martens John W.M. , Anderson Brett D. , Brown William L. , Kalli Kimberly R. , Kaufmann Scott H. , Harris Reuben S.
Published: April 2023

Table S1 has RTqPCR primers and probe information. Table S2 has clinical information for the Dutch cohort. Table S3 has a summary of TCGA samples used in our analyses. Figure S1 has RTqPCR assay validation data. Figure S2 shows clinical correlations of APOBEC3G expression in independent cohorts.
Sup Fig. 3 from Modulation of Navitoclax Sensitivity by Dihydroartemisinin-Mediated MCL-1 Repression in BCR-ABL+ B-Lineage Acute Lymphoblastic Leukemia
Authors: Budhraja Amit , Turnis Meghan E. , Churchman Michelle L. , Kothari Anisha , Yang Xue , Xu Haiyan , Kaminska Ewa , Panetta John C. , Finkelstein David , Mullighan Charles G. , Opferman Joseph T.
Published: April 2023

Loss of NOXA expression does not prevent DHA-induced repression of MCL-1.
Sup Fig 2 from Modulation of Navitoclax Sensitivity by Dihydroartemisinin-Mediated MCL-1 Repression in BCR-ABL+ B-Lineage Acute Lymphoblastic Leukemia
Authors: Budhraja Amit , Turnis Meghan E. , Churchman Michelle L. , Kothari Anisha , Yang Xue , Xu Haiyan , Kaminska Ewa , Panetta John C. , Finkelstein David , Mullighan Charles G. , Opferman Joseph T.
Published: April 2023

DHA treatment abrogates MCL-1 protein expression by post-transcriptional mechanism
Sup Fig 1 from Modulation of Navitoclax Sensitivity by Dihydroartemisinin-Mediated MCL-1 Repression in BCR-ABL+ B-Lineage Acute Lymphoblastic Leukemia
Authors: Budhraja Amit , Turnis Meghan E. , Churchman Michelle L. , Kothari Anisha , Yang Xue , Xu Haiyan , Kaminska Ewa , Panetta John C. , Finkelstein David , Mullighan Charles G. , Opferman Joseph T.
Published: April 2023

MCL-1 is repressed by DHA and Ectopic MCL-1 expression renders BCR-ABL+ B-ALL cells resistant to DHA-induced killing
Supplementary Tables from The Longitudinal Transcriptional Response to Neoadjuvant Chemotherapy with and without Bevacizumab in Breast Cancer
Authors: Silwal-Pandit Laxmi , Nord Silje , von der Lippe Gythfeldt Hedda , Møller Elen K. , Fleischer Thomas , Rødland Einar , Krohn Marit , Borgen Elin , Garred Øystein , Olsen Tone , Vu Phuong , Skjerven Helle , Fangberget Anne , Holmen Marit M. , Schlitchting Ellen , Wille Elisabeth , Nordberg Stokke Mette , Moen Vollan Hans Kristian , Kristensen Vessela , Langerød Anita , Lundgren Steinar , Wist Erik , Naume Bjørn , Lingjærde Ole Christian , Børresen-Dale Anne-Lise , Engebraaten Olav
Published: April 2023

Table S1: Genes significantly differentially expressed in samples with pathological complete response compared to those without in the Combination arm. Table S2: DAVID analysis of 720 differentially expressed genes in tumors that achieved pathological complete reponse compared to those that did not, in the combination arm. Table S3 : Genes significantly differentially expressed in samples with pathological complete response compared to those without in the Chemotherapy arm. Table S4: DAVID analysis of 1243 differentially expressed genes in tumors that achieved pathological complete reponse compared to those that did not, in the chemotherapy arm. Table S5 : List of genes with significant lower expression in week 12 samples treated with combination therapy compared to those treated with chemotherapy Table S6: DAVID analysis of 42 differentially expressed genes in week-12 tumors in the combination arm compared to chemotherapy arm. Table S7 : Differentially expressed genes between week-0 and week-12 in Basal-like tumors treated with combination therapy Table S8 : Differentially expressed genes between week-0 and week-12 Luminal B tumors treated with combination therapy Table S9 : Differentially expressed genes between week-0 and week-12 Luminal A tumors treated with combination therapy Table S10: Differentially expressed genes between week-0 and week-12 Basal-like tumors treated with chemotherapy Table S11 : Differentially expressed genes between week-0 and week-12 Luminal B tumors treated with chemotherapy Table S12 : Differentially expressed genes between week-0 and week-12 Luminal A tumors treated with chemotherapy Table S13: Pathways significantly altered between Chemotherapy and Combination therapy arms from week-0 to week-12 LuminalB samples Table S14: Pathways significantly altered between anthracycline and taxane treatment in the Luminal A samples in chemotherapy arm
Figure S1, Figure S2 from The Longitudinal Transcriptional Response to Neoadjuvant Chemotherapy with and without Bevacizumab in Breast Cancer
Authors: Silwal-Pandit Laxmi , Nord Silje , von der Lippe Gythfeldt Hedda , Møller Elen K. , Fleischer Thomas , Rødland Einar , Krohn Marit , Borgen Elin , Garred Øystein , Olsen Tone , Vu Phuong , Skjerven Helle , Fangberget Anne , Holmen Marit M. , Schlitchting Ellen , Wille Elisabeth , Nordberg Stokke Mette , Moen Vollan Hans Kristian , Kristensen Vessela , Langerød Anita , Lundgren Steinar , Wist Erik , Naume Bjørn , Lingjærde Ole Christian , Børresen-Dale Anne-Lise , Engebraaten Olav
Published: April 2023

Supplementary figures as referred to in the manuscript
Supp Fig S2 from MSH2 Loss in Primary Prostate Cancer
Authors: Guedes Liana B. , Antonarakis Emmanuel S. , Schweizer Michael T. , Mirkheshti Nooshin , Almutairi Fawaz , Park Jong Chul , Glavaris Stephanie , Hicks Jessica , Eisenberger Mario A. , De Marzo Angelo M. , Epstein Jonathan I. , Isaacs William B. , Eshleman James R. , Pritchard Colin C. , Lotan Tamara L.
Published: April 2023

Hematoxylin and eosin staining of representative primary prostate tumors with MSH2 loss. Standard tissue sections of tumor with MSH2 loss demonstrates generally poorly differentiated morphology with Gleason patterns 4 and 5 among adenocarcinoma cases (19236, 22966, 34128) and standard small cell carcinoma morphology in 25566. Variable lymphocytic infiltrate is present from case to case. All photomicrographs are reduced from 100x.
Supplementary Figures 1-8 from Expression of PD-L1 in Hormone-naïve and Treated Prostate Cancer Patients Receiving Neoadjuvant Abiraterone Acetate plus Prednisone and Leuprolide
Authors: Calagua Carla , Russo Joshua , Sun Yue , Schaefer Rachel , Lis Rosina , Zhang Zhenwei , Mahoney Kathleen , Bubley Glenn J. , Loda Massimo , Taplin Mary-Ellen , Balk Steven P. , Ye Huihui
Published: April 2023

Figure S1 Staining of four PD-L1 antibody clones in human placenta tissue (x 200); Figure S2 Staining of three PD-L1 antibody clones in â€œsausageâ€� test block; Figure S3 Staining of three PD-L1 antibody clones in two cases of untreated PCa that were PD-L1-positive (x 400); Figure S4 Staining of three PD-L1 antibody clones in two cases of Neo-AAPL treated PCa that were PD-L1-positive (x 400); Figure S5 PD-L1 expression in six tumors with staining in 1-4% tumor cells; Figure S6 A, Dual immunostain for PD-L1 (E1L3N, brown chromogen) and CK18 (red chromogen) of a tumor (case UN116) with PD-L1 staining in 1-4% tumor cells (x 1,000); Figure S7 Correlation of PD-L1 expression with tumor-infiltrating CD8+ T cells and PD-1+ cells in two Neo-AAPL treated tumors (x 400); Figure S8 The densities of tumor-infiltrating immune cells that were positive for CD3, CD8, and PD-1, per 100 tumor cells, were plotted in PD-L1- positive and -negative cases (N =14), regardless of treatment status (upper panel), with or without Neo-AAPL treatment (bottom panel).
Supplementary from Perioperative COX-2 and β-Adrenergic Blockade Improves Metastatic Biomarkers in Breast Cancer Patients in a Phase-II Randomized Trial
Authors: Shaashua Lee , Shabat-Simon Maytal , Haldar Rita , Matzner Pini , Zmora Oded , Shabtai Moshe , Sharon Eran , Allweis Tanir , Barshack Iris , Hayman Lucile , Arevalo Jesusa , Ma Jeffrey , Horowitz Maya , Cole Steven , Ben-Eliyahu Shamgar
Published: April 2023

Detailed methods, rationale of study design and procedure, and safety concerns
Supplementary Figure Legends from Expression of PD-L1 in Hormone-naïve and Treated Prostate Cancer Patients Receiving Neoadjuvant Abiraterone Acetate plus Prednisone and Leuprolide
Authors: Calagua Carla , Russo Joshua , Sun Yue , Schaefer Rachel , Lis Rosina , Zhang Zhenwei , Mahoney Kathleen , Bubley Glenn J. , Loda Massimo , Taplin Mary-Ellen , Balk Steven P. , Ye Huihui
Published: April 2023

Supplementary Figure Legends
Supplementary Figures S1-S11 from Platinum-Based Chemotherapy Induces Methylation Changes in Blood DNA Associated with Overall Survival in Patients with Ovarian Cancer
Authors: Flanagan James M. , Wilson Angela , Koo Chail , Masrour Nahal , Gallon John , Loomis Erick , Flower Kirsty , Wilhelm-Benartzi Charlotte , Hergovich Alexander , Cunnea Paula , Gabra Hani , Braicu Elena Ioana , Sehouli Jalid , Darb-Esfahani Silvia , Vanderstichele Adriaan , Vergote Ignace , Kreuzinger Caroline , Castillo-Tong Dan Cacsire , Wisman G. Bea A. , Berns Els MJJ , Siddiqui Nadeem , Paul James , Brown Robert
Published: April 2023

Supplementary Figure S1: Clinical Study Schematic. Supplementary Figure S2: Significant changes in blood DNA methylation at time of ovarian cancer relapse compared to at presentation. Supplementary Figure S3: Methylation profiles of blood DNA at time of ovarian cancer relapse predict overall survival. Supplementary Figure S4: Pyrosequencing Validation of blood DNA at time of ovarian cancer relapse predict overall survival. Supplementary Figure S5. Methylation profile validation of tumour DNA at time of ovarian cancer relapse predicts overall survival. Supplementary Figure S6: Deriving clusters using methylation levels of these 8 probes in blood DNA at the time of presentation neither predicts time to first progression nor overall survival. Supplementary Figure S7. Clonal variation in MLH1- and MLH1+ cell lines. Supplementary Figure S8. Cisplatin treatment and long term growth does not affect cisplatin sensitivity of MLH1+ or MLH1- clones. Supplementary Figure S9. Bisulphite pyrosequencing validates five CpG sites. Supplementary Figure S10. Dinucleotide enrichment analysis. Supplementary Figure S11. Mechanism for platinum-induced methylation changes in MLH1-deficient and -proficient cells.
Supplemental material from Use of Liquid Biopsies in Clinical Oncology: Pilot Experience in 168 Patients
Authors: Schwaederle Maria , Husain Hatim , Fanta Paul T. , Piccioni David E. , Kesari Santosh , Schwab Richard B. , Patel Sandip P. , Harismendy Olivier , Ikeda Megumi , Parker Barbara A. , Kurzrock Razelle
Published: April 2023

Supplemental Table 1. Guardant360 54 gene cell-free DNA NGS panel. Complete exon coverage for genes in bold. Unbolded genes had critical exon coverage. Supplemental Table 2. Frequency of patients with metastatic/recurrent/advanced unresectable disease Supplemental Table 3. List of the 12 evaluable patients treated with a matched therapy targeting {greater than or equal to} 1 alteration detected by the ctDNA test. Supplemental Figure 1. Diagram of the population analyzed for treatment outcome
Supplementary text from microRNA-221 Enhances MYCN via Targeting Nemo-like Kinase and Functions as an Oncogene Related to Poor Prognosis in Neuroblastoma
Authors: He Xiao-yan , Tan Zheng-lan , Mou Qin , Liu Fang-jie , Liu Shan , Yu Chao-wen , Zhu Jin , Lv Lin-ya , Zhang Jun , Wang Shan , Bao Li-ming , Peng Bin , Zhao Hui , Zou Lin
Published: April 2023

Supplementary data
Supplementary figure 2 from microRNA-221 Enhances MYCN via Targeting Nemo-like Kinase and Functions as an Oncogene Related to Poor Prognosis in Neuroblastoma
Authors: He Xiao-yan , Tan Zheng-lan , Mou Qin , Liu Fang-jie , Liu Shan , Yu Chao-wen , Zhu Jin , Lv Lin-ya , Zhang Jun , Wang Shan , Bao Li-ming , Peng Bin , Zhao Hui , Zou Lin
Published: April 2023

miR-221 enhances the expression of MYCN mRNA in NB cells.
Figure S1 from Ex Vivo PD-L1/PD-1 Pathway Blockade Reverses Dysfunction of Circulating CEA-Specific T Cells in Pancreatic Cancer Patients
Authors: Chen Yuan , Xue Shao-An , Behboudi Shahriar , Mohammad Goran H. , Pereira Stephen P. , Morris Emma C.
Published: April 2023

Figure S1 shows antigen-specific CD8+ T-cell responses in pancreatic cancer patients. PBMC isolated from 13 pancreatic cancer (PC) patients and 10 healthy controls were cultured for nine days in the presence of each one of a library of 3 different CEA-derived antigens. After stimulation, cells were harvested and re-challenged with either the respective peptides or irrelevant peptides, as controls, for 5 hours, in the presence of Brefeldin A. Intracellular staining was then performed to assess the levels of IFN-γ production by CD8+ T cells. Antigen-specific response was defined as a frequency of IFN-γ+ cells within the CD8+ T-cell population at least two-fold higher than that obtained upon re-challenge with an irrelevant peptide control. (A) Frequency of pancreatic cancer patients and healthy controls who were able to mount CEA-specific responses upon stimulation with different pancreatic CEA peptides (Responders). Bars indicate frequencies referring to either the number of pancreatic patients out of a total of 13, or the number of healthy controls out of a total of 10, who were found to be able to mount specific CD8+ T cell responses. (B) IFN-γ production by CD8+ T cells of pancreatic cancer patients and healthy controls after stimulation with either CEA691 or Telomerase540 (control peptide). Each symbol represents one individual and horizontal lines represent the median. (C) Representative dot-plots of CD8+ T-cell IFN-γ production upon stimulation with either CEA691 or Mucin12 in pancreatic cancer patients (top dot-plots) and healthy controls (bottom dot-plots). The irrelevant peptides used to address CEA691-specific responses were CEA605, respectively.
Supplementary legend from Dendritic Cell Vaccination Enhances Immune Responses and Induces Regression of HER2pos DCIS Independent of Route: Results of Randomized Selection Design Trial
Authors: Lowenfeld Lea , Mick Rosemarie , Datta Jashodeep , Xu Shuwen , Fitzpatrick Elizabeth , Fisher Carla S. , Fox Kevin R. , DeMichele Angela , Zhang Paul J. , Weinstein Susan P. , Roses Robert E. , Czerniecki Brian J.
Published: April 2023

Supplementary legend
Supplemental Figure 3 from Dendritic Cell Vaccination Enhances Immune Responses and Induces Regression of HER2pos DCIS Independent of Route: Results of Randomized Selection Design Trial
Authors: Lowenfeld Lea , Mick Rosemarie , Datta Jashodeep , Xu Shuwen , Fitzpatrick Elizabeth , Fisher Carla S. , Fox Kevin R. , DeMichele Angela , Zhang Paul J. , Weinstein Susan P. , Roses Robert E. , Czerniecki Brian J.
Published: April 2023

Supplemental Figure 3: The CD4pos Th1 immune response in the peripheral blood pre-vaccination and post-vaccination by tumor staging (DCIS vs. IBC), quantified by (A) response repertoire and (B) cumulative response
Supplementary Figure S3 from TGFβR1 Blockade with Galunisertib (LY2157299) Enhances Anti-Neuroblastoma Activity of the Anti-GD2 Antibody Dinutuximab (ch14.18) with Natural Killer Cells
Authors: Tran Hung C. , Wan Zesheng , Sheard Michael A. , Sun Jianping , Jackson Jeremy R. , Malvar Jemily , Xu Yibing , Wang Larry , Sposto Richard , Kim Eugene S. , Asgharzadeh Shahab , Seeger Robert C.
Published: April 2023

Supplementary Figure S3 presents meta-analyses of tumor growth in mice treated with and without galunisertib and dinutuximab.
Table S2 from Dual Suppressive Effect of miR-34a on the FOXM1/eEF2-Kinase Axis Regulates Triple-Negative Breast Cancer Growth and Invasion
Authors: Bayraktar Recep , Ivan Cristina , Bayraktar Emine , Kanlikilicer Pinar , Kabil Nashwa N. , Kahraman Nermin , Mokhlis Hamada A. , Karakas Didem , Rodriguez-Aguayo Cristian , Arslan Ahmet , Sheng Jianting , Wong Stephen , Lopez-Berestein Gabriel , Calin George A. , Ozpolat Bulent
Published: April 2023

RPPA results revealed an array of altered proteins in MDA-MB-231 and MDA-MB-436 cells.
Figure S3 from Dual Suppressive Effect of miR-34a on the FOXM1/eEF2-Kinase Axis Regulates Triple-Negative Breast Cancer Growth and Invasion
Authors: Bayraktar Recep , Ivan Cristina , Bayraktar Emine , Kanlikilicer Pinar , Kabil Nashwa N. , Kahraman Nermin , Mokhlis Hamada A. , Karakas Didem , Rodriguez-Aguayo Cristian , Arslan Ahmet , Sheng Jianting , Wong Stephen , Lopez-Berestein Gabriel , Calin George A. , Ozpolat Bulent
Published: April 2023

In vivo nanoliposomal miR-34a treatment is safe and effectively suppresses eEF2K and FOXM1 protein expression in TNBC tumors.
Supplemental Material-4: Application to SWOG S0819. from Biomarker-Stratified Phase III Clinical Trials: Enhancement with a Subgroup-Focused Sequential Design
Authors: Matsui Shigeyuki , Crowley John
Published: April 2023

Application to SWOG S0819.
Figure S5 from The NOTCH4–HEY1 Pathway Induces Epithelial–Mesenchymal Transition in Head and Neck Squamous Cell Carcinoma
Authors: Fukusumi Takahito , Guo Theresa W. , Sakai Akihiro , Ando Mizuo , Ren Shuling , Haft Sunny , Liu Chao , Amornphimoltham Panomwat , Gutkind J. Silvio , Califano Joseph A.
Published: April 2023

Figure S5. Comparison of HNSCC CSCs marker genes between NOTCH4, HEY1 high and low groups using the TCGA data set. ALDH1 expression in si-NOTCH4 and si-HEY1 cells.
Supplementary methods from AZ1366: An Inhibitor of Tankyrase and the Canonical Wnt Pathway that Limits the Persistence of Non–Small Cell Lung Cancer Cells Following EGFR Inhibition
Authors: Scarborough Hannah A. , Helfrich Barbara A. , Casás-Selves Matias , Schuller Alwin G. , Grosskurth Shaun E. , Kim Jihye , Tan Aik-Choon , Chan Daniel C. , Zhang Zhiyong , Zaberezhnyy Vadym , Bunn Paul A. , DeGregori James
Published: April 2023

Supplementary methods and materials
sup 5 from Personalized RNA Medicine for Pancreatic Cancer
Authors: Gilles Maud-Emmanuelle , Hao Liangliang , Huang Ling , Rupaimoole Rajesha , Lopez-Casas Pedro P. , Pulver Emilia , Jeong Jong Cheol , Muthuswamy Senthil K. , Hidalgo Manuel , Bhatia Sangeeta N. , Slack Frank J.
Published: April 2023

Supplemental Figure 5. A) Representatives PDO 286 images and metabolic activity measured from MTT assay after repeated TPN-21 or gemcitabine treatments (100nM) or both treatments. Scale bars 1000μm. B) Quantification of organoid size after treatments. Organoids size was measure through ImageJ software on a total of ⩾ 35 spheroids and are presented in arbitrary units (UA). Error bars, mean {plus minus} s.d *P = 0.01- 0.05; **P = 0.001-0.01; ***P < 0.001; ****P < 0.0001 N.S., not significant, two-tailed ttest; n = 3 biological replicates.
Supplementary Figure S1 from Efficacy, Safety, and Pharmacokinetics of Axitinib in Nasopharyngeal Carcinoma: A Preclinical and Phase II Correlative Study
Authors: Hui Edwin P. , Ma Brigette B. Y. , Loong Herbert H. F. , Mo Frankie , Li Leung , King Ann D. , Wang Ki , Ahuja Anil T. , Chan Charles M. L. , Hui Connie W. C. , Wong Chi H. , Chan Anthony T. C.
Published: April 2023

Survival analysis of the study cohort.
sup 2 from Personalized RNA Medicine for Pancreatic Cancer
Authors: Gilles Maud-Emmanuelle , Hao Liangliang , Huang Ling , Rupaimoole Rajesha , Lopez-Casas Pedro P. , Pulver Emilia , Jeong Jong Cheol , Muthuswamy Senthil K. , Hidalgo Manuel , Bhatia Sangeeta N. , Slack Frank J.
Published: April 2023

Supplemental Figure 2. A) Relative expression Left panel: Mean of fluorescence and right panel: qPCR validation of miR-21-5p expression level in the set of cell lines, 3D-models and organoid compared to normal controls. B) qPCR analysis of PDCD4 and PTEN expression levels in the PANC1 stable cell lines (Lenti-21) inhibiting miR- 21 activity (pLenti-III-miR-off). C) qRT-PCR of miR-21-5p expression after lipofectamine transfection of PANC1, BxPC3 and PL-45 cells with anti-miR-21 inhibitor (mirVana ®) at the dose of 50nM after 48h. For qPCR each miRNA sample was normalized on the basis of it's 18s content and on the basis of GAPDH for mRNAs.
Sup. Figure 8: Foretinib treatment was feasible in the liver metastasis and brain metastasis-mimicking models obtained using KM12SM-ER cells. from Foretinib Overcomes Entrectinib Resistance Associated with the NTRK1 G667C Mutation in NTRK1 Fusion–Positive Tumor Cells in a Brain Metastasis Model
Authors: Nishiyama Akihiro , Yamada Tadaaki , Kita Kenji , Wang Rong , Arai Sachiko , Fukuda Koji , Tanimoto Azusa , Takeuchi Shinji , Tange Shoichiro , Tajima Atsushi , Furuya Noritaka , Kinoshita Takayoshi , Yano Seiji
Published: April 2023

Body weights of treated mice in the (A) liver metastasis model (Fig. 5) and (B) brain metastasis-mimicking model (Fig. 6) were evaluated.
Supplemental methods from A Phase I Study of CPI-613 in Combination with High-Dose Cytarabine and Mitoxantrone for Relapsed or Refractory Acute Myeloid Leukemia
Authors: Pardee Timothy S. , Anderson Rebecca G. , Pladna Kristin M. , Isom Scott , Ghiraldeli Lais P. , Miller Lance D. , Chou Jeff W. , Jin Guangxu , Zhang Wei , Ellis Leslie R. , Berenzon Dmitriy , Howard Dianna S. , Hurd David D. , Manuel Megan , Dralle Sarah , Lyerly Susan , Powell Bayard L.
Published: April 2023

Supplemental methods
Supplemental Files_Clean version from Long-term Follow-up of Treatment with Ibrutinib and Rituximab in Patients with High-Risk Chronic Lymphocytic Leukemia
Authors: Jain Preetesh , Keating Michael J. , Wierda William G. , Sivina Mariela , Thompson Philip A. , Ferrajoli Alessandra , Estrov Zeev , Kantarjian Hagop , O'Brien Susan , Burger Jan A.
Published: April 2023

Supplemental Files_Clean version
Supplemental Figure 3 from Long-term Follow-up of Treatment with Ibrutinib and Rituximab in Patients with High-Risk Chronic Lymphocytic Leukemia
Authors: Jain Preetesh , Keating Michael J. , Wierda William G. , Sivina Mariela , Thompson Philip A. , Ferrajoli Alessandra , Estrov Zeev , Kantarjian Hagop , O'Brien Susan , Burger Jan A.
Published: April 2023

Changes in serum levels of immunoglobulins on treatment with ibrutinib and rituximab (IR) over time.
Supplemental Figure 2 from Long-term Follow-up of Treatment with Ibrutinib and Rituximab in Patients with High-Risk Chronic Lymphocytic Leukemia
Authors: Jain Preetesh , Keating Michael J. , Wierda William G. , Sivina Mariela , Thompson Philip A. , Ferrajoli Alessandra , Estrov Zeev , Kantarjian Hagop , O'Brien Susan , Burger Jan A.
Published: April 2023

Changes in hematologic parameters on treatment with ibrutinib and rituximab up to 3 years.
Movie S4 from Induction of Telomere Dysfunction Prolongs Disease Control of Therapy-Resistant Melanoma
Authors: Zhang Gao , Wu Lawrence W. , Mender Ilgen , Barzily-Rokni Michal , Hammond Marc R. , Ope Omotayo , Cheng Chaoran , Vasilopoulos Themistoklis , Randell Sergio , Sadek Norah , Beroard Aurelie , Xiao Min , Tian Tian , Tan Jiufeng , Saeed Umar , Sugarman Eric , Krepler Clemens , Brafford Patricia , Sproesser Katrin , Murugan Sengottuvelan , Somasundaram Rajasekharan , Garman Bradley , Wubbenhorst Bradley , Woo Jonathan , Yin Xiangfan , Liu Qin , Frederick Dennie T. , Miao Benchun , Xu Wei , Karakousis Giorgos C. , Xu Xiaowei , Schuchter Lynn M. , Mitchell Tara C. , Kwong Lawrence N. , Amaravadi Ravi K. , Lu Yiling , Boland Genevieve M. , Wei Zhi , Nathanson Katherine , Herbig Utz , Mills Gordon B. , Flaherty Keith T. , Herlyn Meenhard , Shay Jerry W.
Published: April 2023

Time-lapse imaging of A375(Fucci2)-BR cells treated with 6-thio-dG.
Supplementary Figure 2 from Loss of SMAD4 Promotes Lung Metastasis of Colorectal Cancer by Accumulation of CCR1+ Tumor-Associated Neutrophils through CCL15-CCR1 Axis
Authors: Yamamoto Takamasa , Kawada Kenji , Itatani Yoshiro , Inamoto Susumu , Okamura Ryosuke , Iwamoto Masayoshi , Miyamoto Ei , Chen-Yoshikawa Toyofumi F. , Hirai Hideyo , Hasegawa Suguru , Date Hiroshi , Taketo Makoto M. , Sakai Yoshiharu
Published: April 2023

A) Kaplan-Meier curves of RFS in CRC patients after curative pulmonary resection. B) Effect of T factor of primary CRC on RFS after curative pulmonary resection. C) Effect of N factor of primary CRC on RFS after curative pulmonary resection. D) Effect of preoperative CEA level on RFS after curative pulmonary resection.
Supplementary Figure 1 from Loss of SMAD4 Promotes Lung Metastasis of Colorectal Cancer by Accumulation of CCR1+ Tumor-Associated Neutrophils through CCL15-CCR1 Axis
Authors: Yamamoto Takamasa , Kawada Kenji , Itatani Yoshiro , Inamoto Susumu , Okamura Ryosuke , Iwamoto Masayoshi , Miyamoto Ei , Chen-Yoshikawa Toyofumi F. , Hirai Hideyo , Hasegawa Suguru , Date Hiroshi , Taketo Makoto M. , Sakai Yoshiharu
Published: April 2023

A) Western blot of SMAD4. B) Quantitative RT-PCR of CCL15. C) Western blot of SMAD proteins. D) Quantitative RT-PCR of CCL15. E)Immunohistochemistry of metastatic foci. F) Cell proliferation. G) Experimental schedule. H) Relative quantification of the lung metastatic.
Supplementary Figure 3 from Somatic and Germline TP53 Alterations in Second Malignant Neoplasms from Pediatric Cancer Survivors
Authors: Sherborne Amy L. , Lavergne Vincent , Yu Katharine , Lee Leah , Davidson Philip R. , Mazor Tali , Smirnoff Ivan V. , Horvai Andrew E. , Loh Mignon , DuBois Steven G. , Goldsby Robert E. , Neglia Joseph P. , Hammond Sue , Robison Leslie L. , Wustrack Rosanna , Costello Joseph F. , Nakamura Alice O. , Shannon Kevin M. , Bhatia Smita , Nakamura Jean L.
Published: April 2023

Supplementary Figure 3: Somatic variants in radiation-induced SMNs Frequencies of specific types of base substitutions in SNVs (synonymous and non-synonymous SNVs) pooled from all samples are shown.
Supplementary Figure 2 from Somatic and Germline TP53 Alterations in Second Malignant Neoplasms from Pediatric Cancer Survivors
Authors: Sherborne Amy L. , Lavergne Vincent , Yu Katharine , Lee Leah , Davidson Philip R. , Mazor Tali , Smirnoff Ivan V. , Horvai Andrew E. , Loh Mignon , DuBois Steven G. , Goldsby Robert E. , Neglia Joseph P. , Hammond Sue , Robison Leslie L. , Wustrack Rosanna , Costello Joseph F. , Nakamura Alice O. , Shannon Kevin M. , Bhatia Smita , Nakamura Jean L.
Published: April 2023

Supplementary Figure 2 shows the exome coverage achieved with whole exome sequencing.
Supplemental Figure 4 from Mitochondrial Inhibition Augments the Efficacy of Imatinib by Resetting the Metabolic Phenotype of Gastrointestinal Stromal Tumor
Authors: Vitiello Gerardo A. , Medina Benjamin D. , Zeng Shan , Bowler Timothy G. , Zhang Jennifer Q. , Loo Jennifer K. , Param Nesteene J. , Liu Mengyuan , Moral Alec J. , Zhao Julia N. , Rossi Ferdinand , Antonescu Cristina R. , Balachandran Vinod P. , Cross Justin R. , DeMatteo Ronald P.
Published: April 2023

Serum metabolic chemistries and splenic immune cell frequencies in VLX600-treated mice
Supplemental Figure 3 from Mitochondrial Inhibition Augments the Efficacy of Imatinib by Resetting the Metabolic Phenotype of Gastrointestinal Stromal Tumor
Authors: Vitiello Gerardo A. , Medina Benjamin D. , Zeng Shan , Bowler Timothy G. , Zhang Jennifer Q. , Loo Jennifer K. , Param Nesteene J. , Liu Mengyuan , Moral Alec J. , Zhao Julia N. , Rossi Ferdinand , Antonescu Cristina R. , Balachandran Vinod P. , Cross Justin R. , DeMatteo Ronald P.
Published: April 2023

Real-time changes in OCR and ECAR in GIST-T1 cells treated with varying doses of VLX600 + imatinib
Table S4 from Chemical Profiling of Primary Mesothelioma Cultures Defines Subtypes with Different Expression Profiles and Clinical Responses
Authors: Schunselaar Laurel M. , Quispel-Janssen Josine M.M.F. , Kim Yongsoo , Alifrangis Constantine , Zwart Wilbert , Baas Paul , Neefjes Jacques
Published: April 2023

Table S4. Drug screen classification characteristics. Classification of drugs screens in responder, intermediate responder and non-responder groups for drug screens performed on cells from patients without prior treatment and cells of patients that received chemotherapy. For the characteristics analyzed, there was no significant difference between these two groups (p=0.72).
Table S1 from Chemical Profiling of Primary Mesothelioma Cultures Defines Subtypes with Different Expression Profiles and Clinical Responses
Authors: Schunselaar Laurel M. , Quispel-Janssen Josine M.M.F. , Kim Yongsoo , Alifrangis Constantine , Zwart Wilbert , Baas Paul , Neefjes Jacques
Published: April 2023

Table S1. Patient characteristics. (A) Characteristics of all patients where cells could be isolated from pleural fluid. For patients who had multiple cultures at different time points, the number of prior treatment lines was determined at the first successful culture. When we failed to perform a drug screen, the number of prior treatment lines was set at the first culture. (B) Characteristics of patients with a successful drug isolated mesothelioma cells from pleural fluid. (C) Patients characteristics where the drug screen failed.
Supplementary Table S2 from The RNA-binding Protein MEX3B Mediates Resistance to Cancer Immunotherapy by Downregulating HLA-A Expression
Authors: Huang Lu , Malu Shruti , McKenzie Jodi A. , Andrews Miles C. , Talukder Amjad H. , Tieu Trang , Karpinets Tatiana , Haymaker Cara , Forget Marie-Andrée , Williams Leila J. , Wang Zhe , Mbofung Rina M. , Wang Zhi-Qiang , Davis Richard Eric , Lo Roger S. , Wargo Jennifer A. , Davies Michael A. , Bernatchez Chantale , Heffernan Timothy , Amaria Rodabe N. , Korkut Anil , Peng Weiyi , Roszik Jason , Lizée Gregory , Woodman Scott E. , Hwu Patrick
Published: April 2023

Major pathways involving high-comboscore candidates
Supplementary Table S1 from The RNA-binding Protein MEX3B Mediates Resistance to Cancer Immunotherapy by Downregulating HLA-A Expression
Authors: Huang Lu , Malu Shruti , McKenzie Jodi A. , Andrews Miles C. , Talukder Amjad H. , Tieu Trang , Karpinets Tatiana , Haymaker Cara , Forget Marie-Andrée , Williams Leila J. , Wang Zhe , Mbofung Rina M. , Wang Zhi-Qiang , Davis Richard Eric , Lo Roger S. , Wargo Jennifer A. , Davies Michael A. , Bernatchez Chantale , Heffernan Timothy , Amaria Rodabe N. , Korkut Anil , Peng Weiyi , Roszik Jason , Lizée Gregory , Woodman Scott E. , Hwu Patrick
Published: April 2023

A list of all 384 ORFs in the library
Figure S2 from Chemical Profiling of Primary Mesothelioma Cultures Defines Subtypes with Different Expression Profiles and Clinical Responses
Authors: Schunselaar Laurel M. , Quispel-Janssen Josine M.M.F. , Kim Yongsoo , Alifrangis Constantine , Zwart Wilbert , Baas Paul , Neefjes Jacques
Published: April 2023

Fig. S2. CGH profiles at different passages of a primary mesothelioma culture. (A) The log2 ratio of copy number variations (CNV) is depicted for different chromosomes visualized on the x-axis, each chromosome in a different color. The overall profiles in the first two passages indicate the presence of malignant cells as is illustrated by deletion of the P16 locus on chromosome 9 (shown as an zoom-in in the inset). At higher passages the CNV is normalized indicating overgrowth by normal mesothelial cells. (B) Overview of CDKN2A deletion for 5 patients. P1: passage 1, P2: passage 2 , P3: passage 3, P4: passage 4. green: detected, red: not detected, white: not assessed. For patient 3 and 4 no deletion could be detected. For patient 1, 2 and 5 the CDKN2A deletion was detected in early passages. At later passages the deletion could not be detected for patient 1 and 5.
Figures S1-S9 from The RNA-binding Protein MEX3B Mediates Resistance to Cancer Immunotherapy by Downregulating HLA-A Expression
Authors: Huang Lu , Malu Shruti , McKenzie Jodi A. , Andrews Miles C. , Talukder Amjad H. , Tieu Trang , Karpinets Tatiana , Haymaker Cara , Forget Marie-Andrée , Williams Leila J. , Wang Zhe , Mbofung Rina M. , Wang Zhi-Qiang , Davis Richard Eric , Lo Roger S. , Wargo Jennifer A. , Davies Michael A. , Bernatchez Chantale , Heffernan Timothy , Amaria Rodabe N. , Korkut Anil , Peng Weiyi , Roszik Jason , Lizée Gregory , Woodman Scott E. , Hwu Patrick
Published: April 2023

Supplementary Figure S1: Representative flow strategies for detection of apoptotic cells. Supplementary Figure S2: The top 20 candidates with the highest comboscores from the ORF screen. Supplementary Figure S3: MEX3B expression is higher in non-responders than in responders to anti-PD-1 immunotherapy Supplementary Figure S4: Knockdown of MEX3B increases the susceptibility of tumor cells to T cell-mediated cytotoxicity Supplementary Figure S5: Overexpression of HLA-A2 in 2549 melanoma cells results in similar IFNɣ release in MART-1-specific TILs incubated with melanoma cells overexpressing GFP-MEX3B or GFP control Supplementary Figure S6: Overexpression of MEX3B in 2549 melanoma cells decreases surface HLA-A31 expression Supplementary Figure S7: Overexpression of MEX3B in 2549 melanoma cells does not alter HLA-B or HLA-C expression Supplementary Figure S8: Alteration of expression of antigen processing and presentation machinery components upon MEX3B overexpression Supplementary Figure S9: A schematic graph representing transcription factors that may regulate MEX3B expression.
Supplementary note from RIP1–HAT1–SIRT Complex Identification and Targeting in Treatment and Prevention of Cancer
Authors: Carafa Vincenzo , Nebbioso Angela , Cuomo Francesca , Rotili Dante , Cobellis Gilda , Bontempo Paola , Baldi Alfonso , Spugnini Enrico P. , Citro Gennaro , Chambery Angela , Russo Rosita , Ruvo Menotti , Ciana Paolo , Maravigna Luca , Shaik Jani , Radaelli Enrico , De Antonellis Pasquale , Tarantino Domenico , Pirolli Adele , Ragno Rino , Zollo Massimo , Stunnenberg Hendrik G. , Mai Antonello , Altucci Lucia
Published: April 2023

supplementary chemistry
Supplementary Table 1 from Influencing the Tumor Microenvironment: A Phase II Study of Copper Depletion Using Tetrathiomolybdate in Patients with Breast Cancer at High Risk for Recurrence and in Preclinical Models of Lung Metastases
Authors: Chan Nancy , Willis Amy , Kornhauser Naomi , Ward Maureen M. , Lee Sharrell B. , Nackos Eleni , Seo Bo Ri , Chuang Ellen , Cigler Tessa , Moore Anne , Donovan Diana , Vallee Cobham Marta , Fitzpatrick Veronica , Schneider Sarah , Wiener Alysia , Guillaume-Abraham Jessica , Aljom Elnaz , Zelkowitz Richard , Warren J. David , Lane Maureen E. , Fischbach Claudia , Mittal Vivek , Vahdat Linda
Published: April 2023

This is the demographics table containing brief summary of baseline patient characteristics of patients enrolled on trial.
Supplementary Figures from RIP1–HAT1–SIRT Complex Identification and Targeting in Treatment and Prevention of Cancer
Authors: Carafa Vincenzo , Nebbioso Angela , Cuomo Francesca , Rotili Dante , Cobellis Gilda , Bontempo Paola , Baldi Alfonso , Spugnini Enrico P. , Citro Gennaro , Chambery Angela , Russo Rosita , Ruvo Menotti , Ciana Paolo , Maravigna Luca , Shaik Jani , Radaelli Enrico , De Antonellis Pasquale , Tarantino Domenico , Pirolli Adele , Ragno Rino , Zollo Massimo , Stunnenberg Hendrik G. , Mai Antonello , Altucci Lucia
Published: April 2023

Supplementary Figures
Supplementary Tables 1-3 from Outcomes of Children and Adolescents with Advanced Hereditary Medullary Thyroid Carcinoma Treated with Vandetanib
Authors: Kraft Ira L. , Akshintala Srivandana , Zhu Yuelin , Lei Haiyan , Derse-Anthony Claudia , Dombi Eva , Steinberg Seth M. , Lodish Maya , Waguespack Steven G. , Kapustina Oxana , Fox Elizabeth , Balis Frank M. , Merino Maria J. , Meltzer Paul S. , Glod John W. , Shern Jack F. , Widemann Brigitte C.
Published: April 2023

1) Baseline Patient Characteristics 2) Response Characteristics 3) Hypertension and antihypertensive therapy of patients on vandetanib
Supplementary Figures from Overcoming Resistance to DNA-Targeted Agents by Epigenetic Activation of Schlafen 11 (SLFN11) Expression with Class I Histone Deacetylase Inhibitors
Authors: Tang Sai-Wen , Thomas Anish , Murai Junko , Trepel Jane B. , Bates Susan E. , Rajapakse Vinodh N. , Pommier Yves
Published: April 2023

Supplementary Fig. S1. Romidepsin derepresses SLFN11 expression in cancer cell lines from the NCI-60. Supplementary Fig. S2. Forcing SLFN11 expression sensitizes human colon cancer HCT116 cells to camptothecin. Supplementary Fig. S3. Induction of SLFN11 independently of FLI1, rapid reversal of the romidepsin effect and short half-life of SLN11 transcripts. Supplementary Fig. 4. Derepression of SLFN11 by entinostat sensitizes H82 and HH cells to camptothecin and exhibit additive effect in H446 cells.
Supplement Figures S1-S4 from T-cell Homing Therapy for Reducing Regulatory T Cells and Preserving Effector T-cell Function in Large Solid Tumors
Authors: Hu Jiemiao , Sun Chuang , Bernatchez Chantale , Xia Xueqing , Hwu Patrick , Dotti Gianpietro , Li Shulin
Published: April 2023

Fig. S1. CD4+ T cell infiltration in mouse and human tumor sections. Fig. S2. Correlations between the numbers of infiltrated murine T cells and the ratios of costimulatory and coinhibitory receptors. Fig. S3. Quantitative PCR analysis of CXCL9 and CXCL10 mRNA expression in tumor cells that were treated with doxorubicin. Fig. S4. Induction of CXCL9 and CXCL10 at mRNA levels in LLC and Mel2549 tumors after the treatment with IL-12 plus doxorubicin plus T cell infusion.
Supplemental Material from Integrated Pharmacokinetic/Pharmacodynamic Model of a Bispecific CD3xCD123 DART Molecule in Nonhuman Primates: Evaluation of Activity and Impact of Immunogenicity
Authors: Campagne Olivia , Delmas Audrey , Fouliard Sylvain , Chenel Marylore , Chichili Gurunadh R. , Li Hua , Alderson Ralph , Scherrmann Jean-Michel , Mager Donald E.
Published: April 2023

Supplementary figures and tables Figure S1 PK/PD experimental design. This figure details the dose and sampling strategies for the PK/PD endpoints for all animal groups. Figure S2 Detailed structural PK/PD model of MGD006 administrated in cynomolgus monkeys. This figure supplements Fig. 1. Figure S3 Categorization of anti-drug antibody (ADA) development. This figure describes the method used to categorize the ADA effect in three different groups. Table S1 ADA development groups. This table summarizes the different identified groups and the number of animals in each group. Table S2 Parameter definitions of PK/ADA, total T-cell, and CD123+-cell models. Figure S4 /S5 /S6 Time-course of observed and model-fitted plasma MGD006 concentrations, total T-cell counts, and CD123+-cell counts following continuous 4-day infusion in cynomolgus monkeys. This figure supplements Fig. 3. Figure S7 Goodness-of-fit plots for PK, total T-cell, and CD123+-cell models: individual predictions vs. observations and individual weighted residuals vs. time. Figure S8 Prediction-corrected visual predictive checks (PC-VPC) of PK, total T-cell, and CD123+-cell models. Figure S9 /S10 /S11 External validation of the PK, total T-cell, and CD123+-cell models by VPC with data collected in animals following continous 7-day infusions. These figures supplement Fig. 4.
Supplementary Table 1 from A Prognostic Bio-Model Based on SQSTM1 and N-Stage Identifies Nasopharyngeal Carcinoma Patients at High Risk of Metastasis for Additional Induction Chemotherapy
Authors: Yang Qi , Zhang Meng-Xia , Zou Xiong , Liu You-Ping , You Rui , Yu Tao , Jiang Rou , Zhang Yi-Nuan , Cao Jing-Yu , Hong Ming-Huang , Liu Qing , Guo Ling , Kang Tie-Bang , Zhu Xiao-Feng , Chen Ming-Yuan
Published: April 2023

The primers for qPCR
Supplementary Figure 2 from A Prognostic Bio-Model Based on SQSTM1 and N-Stage Identifies Nasopharyngeal Carcinoma Patients at High Risk of Metastasis for Additional Induction Chemotherapy
Authors: Yang Qi , Zhang Meng-Xia , Zou Xiong , Liu You-Ping , You Rui , Yu Tao , Jiang Rou , Zhang Yi-Nuan , Cao Jing-Yu , Hong Ming-Huang , Liu Qing , Guo Ling , Kang Tie-Bang , Zhu Xiao-Feng , Chen Ming-Yuan
Published: April 2023

The NF-kappa B signaling pathway mediates SQSTM1-induced EMT and metastasis.
Supplemental legend from A Prognostic Bio-Model Based on SQSTM1 and N-Stage Identifies Nasopharyngeal Carcinoma Patients at High Risk of Metastasis for Additional Induction Chemotherapy
Authors: Yang Qi , Zhang Meng-Xia , Zou Xiong , Liu You-Ping , You Rui , Yu Tao , Jiang Rou , Zhang Yi-Nuan , Cao Jing-Yu , Hong Ming-Huang , Liu Qing , Guo Ling , Kang Tie-Bang , Zhu Xiao-Feng , Chen Ming-Yuan
Published: April 2023

Supplemental legend
TableS1 from Protein Kinase C Epsilon Is a Key Regulator of Mitochondrial Redox Homeostasis in Acute Myeloid Leukemia
Authors: Di Marcantonio Daniela , Martinez Esteban , Sidoli Simone , Vadaketh Jessica , Nieborowska-Skorska Margaret , Gupta Anushk , Meadows Jake M. , Ferraro Francesca , Masselli Elena , Challen Grant A. , Milsom Michael D. , Scholl Claudia , Fröhling Stefan , Balachandran Siddharth , Skorski Tomasz , Garcia Benjamin A. , Mirandola Prisco , Gobbi Giuliana , Garzon Ramiro , Vitale Marco , Sykes Stephen M.
Published: April 2023

Supplemental Table 1. Clinical characteristics and mutation status of primary AML samples.
Supplemental Figure Legends from Protein Kinase C Epsilon Is a Key Regulator of Mitochondrial Redox Homeostasis in Acute Myeloid Leukemia
Authors: Di Marcantonio Daniela , Martinez Esteban , Sidoli Simone , Vadaketh Jessica , Nieborowska-Skorska Margaret , Gupta Anushk , Meadows Jake M. , Ferraro Francesca , Masselli Elena , Challen Grant A. , Milsom Michael D. , Scholl Claudia , Fröhling Stefan , Balachandran Siddharth , Skorski Tomasz , Garcia Benjamin A. , Mirandola Prisco , Gobbi Giuliana , Garzon Ramiro , Vitale Marco , Sykes Stephen M.
Published: April 2023

Supplemental Figure Legends
Supplementary Figure 2 from HER3 Targeting Sensitizes HNSCC to Cetuximab by Reducing HER3 Activity and HER2/HER3 Dimerization: Evidence from Cell Line and Patient-Derived Xenograft Models
Authors: Wang Dongsheng , Qian Guoqing , Zhang Hongzheng , Magliocca Kelly R. , Nannapaneni Sreenivas , Amin A.R.M. Ruhul , Rossi Michael , Patel Mihir , El-Deiry Mark , Wadsworth J. Trad , Chen Zhengjia , Khuri Fadlo R. , Shin Dong M. , Saba Nabil F. , Chen Zhuo G.
Published: April 2023

Primary EGFR, HER3 expression in PDX patients
Supplementary Table 1 from Association of AR-V7 and Prostate-Specific Antigen RNA Levels in Blood with Efficacy of Abiraterone Acetate and Enzalutamide Treatment in Men with Prostate Cancer
Authors: Qu Fangfang , Xie Wanling , Nakabayashi Mari , Zhang Haitao , Jeong Seong Ho , Wang Xiaodong , Komura Kazumasa , Sweeney Christopher J. , Sartor Oliver , Lee Gwo-Shu Mary , Kantoff Philip W.
Published: April 2023

AR-V7 and PSA expression by patient's treatment status at time of blood draw